Baseline vitamin D status and clinical outcomes in advanced non-small cell lung cancer patients treated with nivolumab

Abstract Immune checkpoint inhibitors such as nivolumab have brought meaningful benefits to patients with advanced non-small cell lung cancer (NSCLC), yet many patients still experience limited responses. Vitamin D is a key modulator of immune function, and deficiency is common in individuals with c...

Descrición completa

Detalles Bibliográficos

Principais autores:	Gözde Ağdaş, Duygu Bayir, Elif Şahin, Muhammet Cengiz, Deniz Can Güven, Mehmet Salim Demir, Ertuğrul Bayram, Duygu Özaşkın, Meltem Baykara, Oktay Bozkurt, Mevlüde İnanç, Metin Özkan, Ayşe Nuransoy Cengiz, Mustafa Erman, Umut Kefeli, Emel Mutlu Özkan, Erkam Kocaaslan, Devrim Çabuk, Saadettin Kiliçkap, Pervin Can Sanci, Muslih Urun, Teoman Sakalar, Cengiz Akosman, Erdem Kolemen, Ezgi Turkoğlu, Anıl Karakayali, Mustafa Ersoy, Sedat Yildirim, Latif Karahan, Hayati Arvas, Mehmet Mutlu Kidi, Sedat Biter, Berrak Mermit Ercek, Nargiz Majidova, Havva Yesil Cinkir, Aslihan Ezgi Apaydin Rollas, İbrahim Karadağ
Formato:	Artigo
Idioma:	Inglês
Publicado:	Nature Portfolio 2026-04-01
Series:	Scientific Reports
Assuntos:	Non-small cell lung cancer Nivolumab Vitamin D deficiency Immunotherapy Prognosis Survival
Acceso en liña:	https://doi.org/10.1038/s41598-026-48955-9
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!